EG8-HM154-100μg / 询价
EG8-HM154-500μg / 询价
EG8-HM154-500μgx2 / 询价
- 客服电话
- 技术支持
Human EGFRVIII Protein
Recombinant Human EGFRVIII Protein is expressed from HEK293 with His tag and Avi tag at the N-Terminus. It contains Leu25-Ser378.[Accession | NP_001333870.1]
The protein has a predicted MW of 41.6 kDa. Due to glycosylation, the protein migrates to 68-80 kDa based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human EGFRVIII on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of Human EGFRVIII is greater than 95% as determined by SEC-HPLC.
Immobilized Human EGFRVIII, His Tag at 1μg/ml (100μl/Well) on the plate. Dose response curve for Anti-EGFRVIII Antibody, hFc Tag with the EC50 of 9.6ng/ml determined by ELISA.
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.
ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2
(1)Pedersen M W , Meltorn M , Damstrup L , et al. The type III epidermal growth factor receptor mutation Biological significance and potential target for anti-cancer therapy[J]. Annals of Oncology, 2001, 12(6):745-760.
